Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Dias, Steven J ^a   Zhou, Xinchun ^b   Ivanovic, Marina ^c   Gailey, Michael P ^c   Dhar, Swati ^a   Zhang, Liangfen ^a   He, Zhi ^b   Penman, Alan D ^a   Vijayakumar, Srinivasan ^b   Levenson, Anait S ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

AFRICAN AMERICAN; ARTICLE; CELL NUCLEUS; ETHNOLOGY; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; PROSTATE TUMOR; RECURRENT DISEASE; RISK ASSESSMENT; STATISTICS; TUMOR RECURRENCE; UNITED STATES; UPREGULATION; CLINICAL TRIAL; EPIDEMIOLOGY; SECONDARY; STATISTICS AND NUMERICAL DATA;

AFRICAN AMERICANS; CELL NUCLEUS; HISTONE DEACETYLASES; HUMANS; IOWA; MALE; MIDDLE AGED; MISSISSIPPI; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROSTATIC NEOPLASMS; RECURRENCE; REPRESSOR PROTEINS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84881363007     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02331     Document Type: Article

References (34)

1. Tollefson, M. K., Karnes, R. J., Rangel, L. J., Bergstralh, E. J. & Boorjian, S. A. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J. Urol. 189, 707-712 (2013).
2. Bryniarski, P., Paradysz, A. & Fryczkowski, M. PSA mass as a marker of prostate cancer progression after radical prostatectomy. Medical science monitor: Int. Med. J. Exp. Clin. Res. 17, CR104-109 (2011).
3. Stephenson, A. J. et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27, 4300-4305 (2009).
4. Salonia, A. et al. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J. Urol. 31, 275-280 (2013).
5. Pierorazio, P. M. et al. Preoperative characteristics of high-Gleason disease predictive of favorable pathological and clinical outcomes at radical prostatectomy. BJU Int. 110, 1122-1128 (2012).
6. Masieri, L. et al. The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml. Int. Urol. Nephrol. 44, 1031-1038 (2012).
7. Han, M. et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 169, 517-523 (2003). (Pubitemid 36132976)
8. Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597 (1999). (Pubitemid 29211767)
9. Stephenson, A. J. et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 23, 7005-7012 (2005).
10. Loeb, S. & Catalona, W. J. Prostate-specific antigen screening: pro. Curr. Opin. Urol. 20, 185-188 (2010).
11. Stephenson, A. J. et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104, 290-298 (2005). (Pubitemid 40993255)
12. Bismar, T. A. et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8, 59-68 (2006).
13. Jemal, A. et al. Cancer Statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
14. Hsing, A. W. & Chokkalingam, A. P. Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413 (2006). (Pubitemid 43253429)
15. Zhou, X., Bigler, S. & Pound, C. Age disparities in diagnosis of prostate cancer between African Americans and Caucasians. Ageing International 37, 186-194 (2012).
16. Bigler, S. A., Pound, C. R. & Zhou, X. A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011, ID 239460 (2011).
17. Rundle, A. et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. Cancer Causes Control 24, 297-303 (2013).
18. Rohrmann, S. et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin. Endocrinol. Metab. 92, 2519-2525 (2007). (Pubitemid 47037352)
19. Caruso, R. P. et al. Altered N-myc downstream-regulated gene 1 protein expression in African-American compared with Caucasian prostate cancer patients. Clin. Cancer Res. 10, 222-227 (2004). (Pubitemid 38114183)
20. Lai, G. Y. et al. Racial variation in umbilical cord blood leptin concentration in male babies. Cancer Epidemiol. Biomarkers Prev. 20, 665-671 (2011).
21. Kai, L. et al. Targeting prostate cancer angiogenesis throughmetastasis-associated protein 1 (MTA1). Prostate 71, 268-280 (2011).
22. Kai, L., Samuel, S. K. & Levenson, A. S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 126, 1538-1548 (2010).
23. Li, K. et al. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor progression and metastasis in prostate cancer. PLoS ONE 8, e57542 (2013).
24. Toh, Y. et al. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br. J. Cancer 79, 1723-1726 (1999). (Pubitemid 29132295)
25. Sasaki, H. et al. Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer 35, 149-154 (2002). (Pubitemid 34136092)
26. Jang, K. S. et al. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 97, 374-379 (2006).
27. Iguchi, H. et al. Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int. J. Oncol. 16, 1211-1214 (2000).
28. Hofer, M. D. et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 64, 825-829 (2004). (Pubitemid 38176879)
29. Higashijima, J. et al. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol. Rep. 26, 343-348 (2011).
30. Toh, Y., Pencil, S. D. & Nicolson, G. L. A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J. Biol. Chem. 269, 22958-22963 (1994).
31. Xue, Y. et al. NURD, a novel complex with both ATP-dependent chromatinremodeling and histone deacetylase activities. Mol. Cell 2, 851-861 (1998). (Pubitemid 128378992)
32. Molli, P. R., Singh, R. R., Lee, S. W. & Kumar, R. MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene. Oncogene 27, 1971-1980 (2008). (Pubitemid 351442737)
33. Kumar, R. et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418, 654-657 (2002).
34. Geng, L. et al. Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries. Open Biochem. J. 2, 100-107 (2008).